Despite their difficult approval pathway, biobetters offer the potential for innovation and decreased healthcare costs.
Niall Dinwoodie
Advertisement
Niall Dinwoodie is head of product characterization, biopharmaceutical services, at Charles River
Articles by Niall Dinwoodie
A good understanding of European regulations governing batch release testing will facilitate your collaboration with a contract laboratory.
Advertisement
Latest Updated Articles
Biobetters and the Future Biologics MarketPublished: November 1st 2011 | Updated:
Batch Release Testing: A Geographical Driver For Outsourcing in EuropePublished: April 2nd 2009 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
2
Industry Leaders Detail Transformational Strategies to Mainstream CAR-T Care
3
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
4
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
5
